Cell Therapeutics’ Adaptive Trial Interim Data May Allow For 2007 Lymphoma NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Company says Phase III interim results of pixantrone adaptive trial are “highly significant” and could lead to an NDA submission for relapsed, aggressive non-Hodgkin’s lymphoma.
You may also be interested in...
Cell Therapeutics’ Adaptive Trials For Lymphoma Treatment Pixantrone Could Meet Endpoints Early
Meeting endpoints early would allow NDA filing in second half of 2008, CEO James Bianco tells “The Pink Sheet” DAILY.
Cell Therapeutics’ Adaptive Trials For Lymphoma Treatment Pixantrone Could Meet Endpoints Early
Meeting endpoints early would allow NDA filing in second half of 2008, CEO James Bianco tells “The Pink Sheet” DAILY.
CTI Plans To File Pixantrone For Non-Hodgkin’s Lymphoma In Early 2008
First pixantrone NHL filing likely will be in the “aggressive/salvage setting,” CEO tells “The Pink Sheet” DAILY.